- Home
- ITRG vs BNTC Comparison
ITRG vs BNTC Comparison
Compare ITRG & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | BNTC |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.9M | 396.3M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ITRG | BNTC |
|---|---|---|
| Price | $2.59 | $9.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $6.13 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 1.6M | 161.5K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.41 | N/A |
| Revenue Next Year | $24.58 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $8.52 |
| 52 Week High | $4.87 | $16.76 |
Technical Indicators
Market Signals| Indicator | ITRG | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 44.40 | 29.02 |
| Support Level | $2.21 | N/A |
| Resistance Level | $2.91 | $13.49 |
| Average True Range (ATR) | 0.10 | 0.76 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 12.11 | 22.26 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.